Cargando…

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation

The development of a neuroendocrine phenotype as a mechanism of resistance to hormonal treatment is observed in up to 20% of advanced prostate cancer patients. High grade neuroendocrine prostate cancer (NEPC) is associated to poor prognosis and the therapeutic armamentarium is restricted to platinum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergamini, Marco, Dalla Volta, Alberto, Caramella, Irene, Bercich, Luisa, Fisogni, Simona, Bertoli, Mattia, Valcamonico, Francesca, Grisanti, Salvatore, Poliani, Pietro Luigi, Bertagna, Francesco, Berruti, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354022/ https://www.ncbi.nlm.nih.gov/pubmed/35936689 http://dx.doi.org/10.3389/fonc.2022.937713

Ejemplares similares

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients
por: Dalla Volta, Alberto, et al.
Publicado: (2023)

The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures
por: Dalla Volta, Alberto, et al.
Publicado: (2020)

Immunotherapy failure in adrenocortical cancer: where next?
por: Cosentini, Deborah, et al.
Publicado: (2018)

Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy
por: Cosentini, Deborah, et al.
Publicado: (2021)

PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma
por: Harris, Nathanial, et al.
Publicado: (2023)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
por: Bertagna, Francesco, et al.
Publicado: (2020)

Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study
por: Palumbo, Carlotta, et al.
Publicado: (2021)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Hepatosplenic Candidiasis Detected by (18)F-FDG-PET/CT
por: Albano, Domenico, et al.
Publicado: (2016)

Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET
por: Chau, Matthew, et al.
Publicado: (2022)

Bone Scintigraphy versus PSMA-Targeted PET/CT or PET/MRI in Prostate Cancer: Lessons Learned from Recent Systematic Reviews and Meta-Analyses
por: Dondi, Francesco, et al.
Publicado: (2022)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

Metachronous Brain Tumor in 177Lu-PSMA Scan in a Patient with Metastatic Castration Resistant Prostate Cancer Mimicking Disease Progression
por: Pirayesh, Elahe, et al.
Publicado: (2023)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET
por: McGeorge, Stephen, et al.
Publicado: (2021)

PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study
por: Mattoni, Susanna, et al.
Publicado: (2022)

Predictive and prognostic potential of pretreatment (68)Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
por: Assadi, Majid, et al.
Publicado: (2022)

Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review
por: Rizzo, Alessio, et al.
Publicado: (2023)

Endocrine and Neuroendocrine Tumors: A Special Issue
por: Berruti, Alfredo, et al.
Publicado: (2022)

Pulmonary metastases from malignant epithelioid schwannoma of the arm presenting as fast-growing subsolid nodules: Report of an unusual case
por: Borghesi, Andrea, et al.
Publicado: (2019)

An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
por: Bilinski, Pretoria, et al.
Publicado: (2020)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

Isolated Castrate-resistant Prostate Cancer Metastasis to Both Adrenal Glands Detected on (68)Ga PSMA PET/CT
por: Kanatsız, Osman, et al.
Publicado: (2023)

An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: a case report
por: Celotti, Andrea, et al.
Publicado: (2015)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer
por: Shi, Sheng-Jia, et al.
Publicado: (2019)

Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer
por: Mao, Juanli, et al.
Publicado: (2022)

Neuroendocrine regulation of female aggression
por: Oliveira, Vinícius Elias de Moura, et al.
Publicado: (2022)

A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients
por: Serani, Francesca, et al.
Publicado: (2023)

Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle
por: Berruti, Alfredo, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2jf7lmeevsogo3cfbgaros8ks7